Skip to content

XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Independent Research
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

XORTX Announces Filing of FDA pre-IND Meeting Request Letter

XORTX Announces Filing of FDA pre-IND Meeting Request Letter
XORTX Announces Filing of FDA pre-IND Meeting Request Letter

Press Releases

  • XORTX Highlights New Studies of Acute Kidney Disease Due to COVID-19 Infection September 15, 2020
  • XORTX Files U.S. FDA Pre-IND Meeting Request for XRx-101 (Oxypurinol) COVID-19 Program and Pre-IND Meeting Submission August 31, 2020
  • XORTX Announces Change to Board of Directors August 28, 2020
  • XORTX Appoints Dr. David Sans in New York as Director Corporate Development August 7, 2020
  • XORTX Partners with Mount Sinai’s Icahn School of Medicine on US-based Clinical Trial in COVID-19 August 4, 2020
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress